Greenwich LifeSciences, Inc. (GLSI) Stock Grade

About Greenwich LifeSciences, Inc.'s fundamentals

Greenwich LifeSciences is a small-cap biotech company with a market capitalization of $284.4 million that is not yet profitable, having reported a net loss in its latest annual statement. The company generated no revenue growth year-over-year and maintained a 0.0% net margin, indicating it is still in a development or pre-commercialization phase typical of early-stage biotech firms. With no dividend yield and unavailable profitability metrics like P/E ratio and return on equity, the company's financial performance reflects the characteristics of a pre-revenue or early-revenue biotechnology enterprise.